Maybe someone will take this further and create a molecule that can be used in medical treatment for conditions like depression,' says Himanshu Khandelia. 'I would be very happy if society can use our research. Their research is about studying and describing what happens at the molecular level when psilocin meets a brain cell, penetrates its membrane, and binds to receptors.

The two researchers are neither neuroscientists nor pharmacists, so they currently have no plans on conducting clinical trials or designing new drugs. This knowledge can be used if you want to design a drug that acts like psilocybin,' explained Ali Asghar Hakami Zanjani. We show that psilocin binds stronger than serotonin to a 5-HT 2AR serotonin receptor. 'Previous research has shown that psilocin binds to serotonin receptors in the brain. Together with Ali Asghar Hakami Zanjani, he is interested in understanding what happens at the molecular level when psilocybin enters the body, is converted to psilocin, and reaches the brain. And since psilocybin mushrooms grow everywhere in Denmark-I picked some in Svanninge Bakker-it wasn't difficult to start our research,' said Himanshu Khandelia. 'My interest was piqued when I heard a podcast about treating smoking addiction with psilocybin. The newest study's co-authors are Teresa Quynh Tram Nguyen and Luise Jacobsen. The two researchers have recently published their paper, titled 'The Molecular Basis of the Antidepressant Action of the Magic Mushroom extract, Psilocin.' The article is the third in a series on the same topic from the two researchers ( Interaction of psychedelic tryptamine derivatives with a lipid bilayer and Magic mushroom extracts in lipid membranes). This is also the opinion of University of Southern Denmark researchers Himanshu Khandelia and Ali Asghar Hakami Zanjani from the Department of Physics, Chemistry and Pharmacy. The substance has the potential to revolutionize the way we treat conditions such as severe depression and substance addiction, according to many.

Magic binds